Evidence map›Paper›PMID 32855989›Full record

ArticleOpen forum infectious diseases2020

All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS).

Maroussia Roelens, Barbara Bertisch, Darius Moradpour, Andreas Cerny, Nasser Semmo, Patrick Schmid, Beat Müllhaupt, Olivier Clerc, David Semela, Christoph Junker and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Maroussia RoelensInstitute of Global Health, University of Geneva, Geneva, Switzerland.ORCID 0000-0003-0876-4673
Barbara BertischInstitute of Global Health, University of Geneva, Geneva, Switzerland.ORCID 0000-0003-1725-4245
Darius MoradpourDivision of Gastroenterology and Hepatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Andreas CernyFondazione Epatocentro Ticino, Lugano, Switzerland.
Nasser SemmoDepartment for BioMedical Research, Hepatology, University of Bern, Bern, Switzerland.
Patrick SchmidDivision of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Beat MüllhauptSwiss Hepato-Pancreato-Biliary Center and Department of Gastroenterology and Hepatology, University Hospital, Zürich, Switzerland.
Olivier ClercDepartment of Internal Medicine and Infectious Diseases, Pourtalès Hospital, Neuchâtel, Switzerland.
David SemelaDivision of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Christoph JunkerSwiss Federal Statistical Office, Section Population Health, Neuchâtel, Switzerland.
Francesco NegroDivision of Gastroenterology and Hepatology, University Hospitals Geneva, Geneva, Switzerland.
Olivia KeiserInstitute of Global Health, University of Geneva, Geneva, Switzerland.
Swiss Hepatitis C Cohort Study
Epatocentro Ticino · CHUniversity Hospital of Geneva · CHUniversity of Bern · CHUniversity of Geneva · CHUniversity of Lausanne · CHUniversity of St.Gallen · CHHospital Neuchâtel · CHKantonsspital St. Gallen · CHFederal Statistical Office · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith direct-acting antiviral agents (DAAs), mortality rates and causes of death among persons with hepatitis C virus (HCV) infection may change over time. However, the emergence of such trends may be delayed by the slow progression of chronic hepatitis C. To date, detailed analyses of cause-specific mortality among HCV-infected persons over time remain limited.

methodsWe evaluated changes in causes of death among Swiss Hepatitis C Cohort Study (SCCS) participants from 2008 to 2016. We analyzed risk factors for all-cause and cause-specific mortality, accounting for changes in treatment, fibrosis stage, and use of injectable drugs over time. Mortality ascertainment was completed by linking lost-to-follow-up participants to the Swiss Federal Statistical Office death registry.

resultsWe included 4700 SCCS participants, of whom 478 died between 2008 and 2016. The proportion of unknown causes of death decreased substantially after linkage, from 42% to 10%. Leading causes of death were liver failure (crude death rate 4.4/1000 person-years), liver cancer (3.4/1000 person-years), and nonliver cancer (2.8/1000 person-years), with an increasing proportion of cancer-related deaths over time. Cause-specific analysis showed that persons with sustained virologic response were less at risk for liver-related mortality than those never treated or treated unsuccessfully.

conclusionsAlthough the expected decrease in mortality is not yet observable, causes of death among HCV-infected persons have evolved over time. With the wider use of DAAs, liver-related mortality is expected to decline in the future. Continued monitoring of cause-specific mortality will remain important to assess the long-term effect of DAAs and design effective interventions.

Indexed as

cohorthepatitis Cmortalityrisk factorsSwitzerland

Identifiers

PMID32855989
PMCPMC7443104
OpenAlexW3044863802

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.